Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Mar 22, 2016 5:09pm
137 Views
Post# 24689879

RE:FOR THOSE OF INTEREST: WHEN HDL IS NOT CARDIO PROTECTIVE

RE:FOR THOSE OF INTEREST: WHEN HDL IS NOT CARDIO PROTECTIVEExactly. It's not about just raising HDL levels, it's about HDL function. This new study shows that mutations in scavengor receptor BI, and HDL receptor, result in increased HDL levels but also increased cardiovascular disease. Reminiscent of the CETP story in which CETP inhibitors can elicit tremendous elevations in HDL, but not elicit much, if at all, protection from cardiovascular disease. Fortunately, RVX-208 acts via a distinct mechansim to increase apoAI levels and HDL biogenesis, resulting in an augmentation of not just HDL levels but HDL functionality.

Best regards,

BearDownAZ
Bullboard Posts